Q3 2026 Earnings Call

GLP-1 Momentum Meets Reality

Eli Lilly has transformed into one of the world's most valuable companies on the back of its GLP-1 drugs, Mounjaro for diabetes and Zepbound for obesity. These tirzepatide-based treatments fueled massive revenue jumps through 2025, with full-year sales hitting around $65 billion amid shortages that still constrained supply.

The company entered 2026 with bold guidance: $80 billion to $83 billion in revenue, implying roughly 25% growth, and sharply higher earnings per share. This forecast assumes successful scaling of manufacturing, including new facilities in Virginia, Texas, and Puerto Rico, plus continued strong uptake despite higher prices and emerging competition.

By late October 2026, the third quarter will have captured summer and early fall sales data, a period when seasonal factors and potential new trial readouts or regulatory decisions could influence trajectory. Recent quarters have shown consistent beats on estimates, but the bar is now extraordinarily high; any slowdown in volume growth or signs of payer pushback on coverage could spark volatility.

Non-obvious tensions include the balance between investing heavily in capacity—costly upfront—and protecting margins, which have expanded as high-profit GLP-1s dominate the mix. Pipeline diversification into areas like Alzheimer's (Kisunla) and cancer adds long-term optionality but remains smaller near-term. Meanwhile, competitors advance oral formulations and multi-agonists, potentially eroding Lilly's lead if supply issues persist or if real-world efficacy data diverges from trials.

The stakes involve not just shareholder returns but broader healthcare economics: sustained high sales support massive R&D reinvestment, yet also raise questions about affordability and access for patients facing chronic conditions.